MedTrace Logo

To Evaluate the Safety and Efficacy of NVP-2203 Tablet in Patients

NCT05856487 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 228

Last updated 2024-03-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety NVP-2203 in patients

Conditions

Interventions

DRUG

NVP-2203

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R1

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R2

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R3

Take it once daily for 8 weeks orally.

DRUG

NVP-2203 Placebo

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R1 Placebo

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R2 Placebo

Take it once daily for 8 weeks orally.

DRUG

NVP-2203-R3 Placebo

Take it once daily for 8 weeks orally.

Sponsors & Collaborators

  • NVP Healthcare

    lead INDUSTRY

Principal Investigators

  • SH Lee, MD · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-30
Primary Completion
2024-05-31
Completion
2024-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05856487 on ClinicalTrials.gov